Abstract
Exposure and response prevention (ERP), a form of cognitive-behavioral therapy, stands as an effective primary treatment for obsessive-compulsive disorder (OCD) for children and adolescents as well as adults. However, despite strong evidence supporting ERP’s effectiveness from clinical research and real-world applications, its utilization remains limited. This underuse is often attributed to access barriers such as the scarcity of properly trained therapists, geographical constraints, and costs. Some of these barriers may be addressed with virtual behavioral health, providing ERP for OCD through video teletherapy and supplemented by app-based therapeutic tools and messaging support between sessions. While studies in adults with OCD have shown research efficacy and real-world effectiveness of teletherapy ERP, less is known about outcomes in youth. This study reports on the effectiveness of teletherapy ERP for OCD in the largest sample (N=2173) of child and adolescent patients to date, across the U.S., Canada, Australia, and the UK. Treatment resulted in a median 37.3% decrease in OCD symptoms and 53.4% of youth met full response criteria. Further, there were significant reductions in the severity of concurrent depression, anxiety, and stress symptoms. These outcomes were achieved in a relatively small amount of therapist time (median of 13 appointments and 11.5 hours). The observed effect size was substantial and comparable to in-person ERP outcomes. This remote treatment, assisted by technology, is easily accessible to patients and represents a significant advancement in spreading effective and efficient evidence-based care for OCD.
Competing Interest Statement
Jamie D. Feusner, Nicholas R. Farrell, Mia Nuñez, Nicholas Lume, Catherine W. MacDonald, Patrick B. McGrath, Larry Trusky, Stephen Smith, and Andreas Rhode report personal fees from NOCD Inc.
Clinical Trial
NCT06466447
Funding Statement
This analysis was funded by NOCD
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The University of California Los Angeles IRB has determined the research to be exempt from IRB review and has stated the following: Based on the information that was provided in this application, this project does not meet the definition of Human Subject Research. Thus it is not necessary to submit the application to the IRB for review and approval.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present analysis are available upon reasonable request to the authors
Abbreviations
- OCD
- obsessive-compulsive disorder
- ERP
- exposure and response prevention
- DOCS
- Dimensional Obsessive-Compulsive Scale
- DIAMOND
- Diagnostic Interview for Anxiety, Mood, and OCD and Related Neuropsychiatric Disorders
- DASS-21
- Depression, Anxiety, and Stress Scales